🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
9.00
+0.15 (1.69%)
At close: Nov 20, 2026, 4:00 PM EST
8.90
-0.10 (-1.11%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.

The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease.

Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.

Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Alpha Cognition Inc.
Alpha Cognition logo
CountryUnited States
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees71
CEOMichael McFadden

Contact Details

Address:
1452 Hughes Street, Suite 200
Grapevine, Texas 76051
United States
Phone858 344 4375
Websitealphacognition.com

Stock Details

Ticker SymbolACOG
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001655923
CUSIP Number02074J501
ISIN NumberCA02074J5017
SIC Code2836

Key Executives

NamePosition
Michael E. McFadden B.B.A.Chief Executive Officer and Director
Kenneth Anthony Cawkell B.A., LL.B.Founder, Consultant, Corporate Secretary and Director
Henry H. Du CPAVice President of Finance and Accounting and Interim Chief Financial Officer
Lauren D'Angelo M.B.A.Chief Operating Officer
Dr. Denis G. Kay M.Sc., Ph.D.Chief Scientific Officer
Timothy AyersHead of Compliance
Christine RevealVice President of Marketing and Commercial Strategy

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 12, 20268-KCurrent Report
Nov 12, 202610-QQuarterly Report
Sep 23, 2026SCHEDULE 13GFiling
Aug 13, 202610-QQuarterly Report
Jul 24, 2026SCHEDULE 13G/AFiling
Jun 29, 2026SCHEDULE 13G/AFiling
Jun 23, 20268-KCurrent Report
May 22, 2026SCHEDULE 13G/AFiling
May 14, 202610-QQuarterly Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides